ILM1.DE

Medios AG [ILM1.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ILM1.DE Stock Summary

Top 10 Correlated ETFs

ILM1.DE

Top 10 Correlated Stocks

ILM1.DE

In the News

ILM1.DE Financial details

Company Rating
-
Market Cap
356.61M
Income
18.81M
Revenue
1.78B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
333
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
19.35
Forward P/E
-
PEG
74.5
P/S
0.2
P/B
0.78
P/C
-
P/FCF
12.78
Quick Ratio
1.84
Current Ratio
2.55
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.79
EPS next Y
-
EPS next Q
-
EPS this Y
2.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.35%
Revenue last 5Y
28.13%
Revenue Q/Q
-9.94%
EPS Q/Q
-66.67%
-
-
-
-
SMA20
-
SMA50
-7.69%
SMA100
-7.69%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
4%
ROC
0.06%
Gross Margin
6%
Oper. Margin
2%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.34-20.25
52W High
-41.6%
52W Low
-10.15%
RSI
47
Rel Volume
0.35
Avg Volume
37.83K
Volume
13.3K
Perf Week
0%
Perf Month
-9.03%
Perf Quarter
-23.76%
Perf Half Y
-23.06%
-
-
-
-
Beta
1.071
-
-
Volatility
0.22%, 0.74%
Prev Close
2.82%
Price
11.68
Change
2.64%

Something similar

Top by Market Cap
LLY
AVGO
BRH.DE
BRK-A
DHR-PB
Top Correlated ETFs
SXRJ.DE
IQQS.DE
BATT.L
C007.DE
OM3X.DE
Top Correlated Stocks
DESN.SW
BEKB.BR
GTT.PA
NEX.PA
SGO.PA
Similar Market Cap
VIJIFIN.NS
PABV.F
SRIJ.PA
PBYI
MXCT.L

Company Profile

Healthcare Medical - Distribution
  • Volume Average 37.83K
  • Market Capitalization 356.61M
  • Employee 333
  • CEO Mr. Matthias Gaertner
  • Headquarters Berlin,DE
  • IPO Date 2007-12-28
  • Website https://www.medios.ag

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.